Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionTd Asset Management Inc
Latest Disclosed Ownership281,848 shares
Latest Disclosed Value $ 93,255,048
Td Asset Management Inc reports 4.74% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 11, 2026 - Td Asset Management Inc filed a 13F-HR form disclosing ownership of 281,848 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $80,523,974 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 269,101 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 4.74% during the quarter. The current value of the position is $73,421,404 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 281,848 12,747 4.74 93,255 -12.85 0.0405
2026-02-10 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 269,101 -43,416 -13.89 107,008 -24.91 0.0861
2025-11-10 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 312,517 -128,660 -29.16 142,508 -0.94 0.1157
2025-07-28 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 441,177 -45,407 -9.33 143,863 9.50 0.1228
2025-05-07 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 486,584 -17,454 -3.46 131,387 10.78 0.1209
2025-02-11 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 504,038 15,755 3.23 118,605 -11.64 0.1049
2024-11-01 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 488,283 -1,657 -0.34 134,234 12.75 0.1185
2024-08-02 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 489,940 27,592 5.97 119,055 72.30 0.1110
2024-05-08 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 462,348 -3,737 -0.80 69,098 -22.55 0.0643
2024-02-12 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 466,085 -29,279 -5.91 89,213 1.69 0.0877
2023-10-27 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 495,364 136,283 37.95 87,729 28.63 0.1063
2023-08-09 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 359,081 -783 -0.22 68,204 -5.39 0.0777
2023-05-10 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 359,864 -32,586 -8.30 72,088 -22.71 0.0870
2023-02-07 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 392,450 7,639 1.99 93,266 15.75 0.1151
2022-11-07 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 384,811 -15,457 -3.86 80,575 38.02 0.1009
2022-08-04 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 400,268 -371,802 -48.16 58,379 -53.69 0.0676
2022-05-10 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 772,070 375,597 94.73 126,072 87.51 0.0745
2022-05-10 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 392,682 64,121
2022-02-10 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 396,473 161,789 68.94 67,234 51.74 0.0563
2021-11-09 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 234,684 10,584 4.72 44,310 10.50 0.0460
2021-08-11 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 224,100 32,078 16.71 40,101 47.91 0.0407
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 192,022 16,495 9.40 27,112 18.84 0.0303
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 175,527 8,080 4.83 22,813 -6.43 0.0277
2020-11-10 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 167,447 9,887 6.28 24,380 4.47 0.0338
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 157,560 8,743 5.88 23,336 44.06 0.0332
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 148,817 16,600 12.56 16,199 6.38 0.0274
2020-02-11 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 132,217 18,165 15.93 15,227 66.02 0.0221
2019-11-07 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 114,052 17,800 18.49 9,172 31.33 0.0140
2019-08-01 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 96,252 3,730 4.03 6,984 -19.22 0.0105
2019-05-08 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 92,522 -1,185 -1.26 8,646 26.55 0.0132
2019-02-01 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 93,707 -13,331 -12.45 6,832 -27.07 0.0119
2018-11-01 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 107,038 -19,250 -15.24 9,368 -24.68 0.0139
2018-07-31 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 126,288 -42,608 -25.23 12,438 -38.17 0.0190
2018-05-11 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 168,896 9,950 6.26 20,116 -0.39 0.0308
2018-02-02 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 158,946 20,151 14.52 20,194 23.84 0.0294
2017-11-09 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 138,795 8,877 6.83 16,307 57.37 0.0244
2017-08-01 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 129,918 34,918 36.76 10,362 112.82 0.0163
2017-05-05 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 95,000 2,200 2.37 4,869 40.16 0.0078
2017-02-08 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 92,800 3,262 3.64 3,474 -42.76 0.0059
2016-11-02 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 89,538 258 0.29 6,069 22.51 0.0105
2016-08-04 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 89,280 65,680 278.31 4,954 234.50 0.0090
2016-05-05 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,600 2,300 10.80 1,481 -26.13 0.0028
2016-02-04 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,300 2,200 11.52 2,005 30.62 0.0040
2015-11-12 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,100 1,000 5.52 1,535 -29.26 0.0030
2015-08-11 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,100 3,100 20.67 2,170 38.57 0.0039
2015-04-28 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,000 15,000 0.00 1,566 0.0028
2015-01-30 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -43,100 -100.00 0 -100.00
2014-11-06 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,100 300 0.70 3,366 24.48 0.0058
2014-08-12 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 42,800 -12,800 -23.02 2,704 -27.56 0.0046
2014-05-09 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,600 -5,400 -8.85 3,733 -4.87 0.0068
2014-02-07 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 61,000 -9,700 -13.72 3,924 -13.30 0.0073
2013-11-08 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 70,700 25,700 57.11 4,526 224.44 0.0090
2013-07-24 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,000 45,000 1,395 0.0030
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.